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1  | INTRODUC TION
Despite the non‐vitamin K antagonist oral anticoagulants (NOACs) 
being introduced for stroke prevention in atrial fibrillation (AF) in 
recent years, the vitamin K antagonists (VKAs) are still used as oral 
anticoagulants (OACs) in large number of patients.1,2 Switching from 
one OAC drug to another is common, especially for VKAs to be 
changed to NOACs.3‒6 However, there is lack of evidence from di‐
rect comparisons on the effectiveness and safety of VKAs in those 
who have VKAs initiated following previous use of other OACs (ie, 
“switchers”) and in those who are newly started on VKAs (“new 
starters”).
The effectiveness and safety of different modes of VKA initia‐
tion (ie, VKA “switchers” vs VKA “new starters”) have been based 
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Abstract
Background: To explore differences in outcomes between dose‐adjusted vitamin K 
antagonists (VKAs) “new starters” and “switchers” in patients with nonvalvular atrial 
fibrillation (AF).
Methods: A post hoc analysis was performed to assess the outcome differences be‐
tween VKA “new starters” and “switchers” in AF patients using pooled individual 
patient data of AMADEUS and BOREALIS trials.
Results: A	 total	 of	 4169	AF	patients	were	 included	 in	 the	present	 analysis,	which	
included	1383	“VKA	new	starters”	and	2786	“VKA	switchers”.	VKA	new	starters	had	
higher crude rates of all‐cause mortality (P = .035) and cardiovascular death (P = .047) 
compared to switchers. On multivariable Cox regression analysis, both “new starters” 
and “switchers” showed nonsignificant trends for different risks of stroke/systemic 
thromboembolism	 (SE)	 (hazard	 ratio	 (HR):	 1.66,	 95%CI:	 0.95‐2.90,	P = .08), major 
bleeding	(HR:	1.25,	95%	CI:	0.73‐2.16,	P	=	.42),	and	all‐cause	death	(HR:	1.09,	95%	CI:	
0.75‐1.57, P	=	.65).	On	Kaplan‐Meier	analysis,	both	groups	had	similar	risks	of	stroke/
systemic embolism (P = .09), major bleeding (P = .28), and all‐cause death (P	=	.06).
Conclusions: In this post hoc analysis of clinical trial patients with AF, “new starters” 
and “switchers” for VKA initiation had nonstatistically significant rates of trial‐adjudi‐
cated thromboembolism, major bleeding, and all‐cause mortality.
K E Y W O R D S
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on evidence from “real‐world” studies7,8 and meta‐analyses.9 Patient 
willingness and compliance as well as physician adherence and com‐
pliance may impact on outcomes.10,11
The aim of this analysis was to explore the differences in out‐
comes between VKA “new starters” and “switchers” in patients with 
nonvalvular AF. We performed a post hoc ancillary analysis using 
pooled individual patient data from two randomized, open‐label tri‐
als (AMADEUS and BOREALIS), with negligible subjective intention 
of switching between OACs and trial‐adjudicated outcomes.
2  | METHODS
The full details of the designs of the AMADEUS and BOREALIS 
trials have been described previously, and are summarized in 
Supplemental Methods.12,13 The AMADEUS and BOREALIS trials 
were approved by the institutional review boards and all patients 
provided written informed consent. Patients from the VKA arms 
were categorized into two groups according to their treatment after 
randomization, that is, “VKA new starters” (on VKA and without pre‐
vious VKA treatment) or “VKA switchers” (on VKA and with previous 
VKA treatment).
2.1 | Study endpoints
In this pooled analysis, we included all outcomes collected from the 
initiation of the treatment to the end of the studies. The primary 
analysis of the both trials reported only outcomes collected during 
the on‐treatment period. The primary efficacy outcome of this anal‐
ysis was the composite of stroke and systemic thromboembolism 
(SE). Stroke was further classified into ischemic and nonischemic 
stroke based on brain imaging results. SE was confirmed by angiog‐
raphy, surgery, or autopsy in the original trials. The primary safety 
outcome was major bleeding, as defined on previously published 
criteria.12,13 Other efficacy outcomes of venous thromboembolism, 
myocardial infarction, and safety outcomes of any clinically relevant 
bleeding, intracranial hemorrhage, were defined according to the 
original trials.12,13 All‐cause death and the subgroups of fatal stroke 
and cardiovascular death were also assessed in this analysis.12,13
Only the first event of each outcome and their occurrence date 
were used for analysis. Suspected outcome events in both trials 
were adjudicated by each independent central adjudication commit‐
tee that was blinded to the treatment assignment.
2.2 | Statistical analysis
Baseline characteristics were reported as percentages or mean ± SD. 
Data unavailable when merging the two datasets were treated as 
missing data. Comparisons of the continuous variables were per‐
formed using independent t test. Categorical variables were com‐
pared using Chi‐squared test or Fisher exact test.
Outcomes were expressed by event rate (number per 100 pa‐
tient‐years). Two Cox proportional hazard models were used to 
estimate the hazard ratio (HR) for the outcomes of stroke/SE major 
bleeding and all‐cause death according to stratification of VKA 
switcher/new starter. Model I was adjusted for sex, age, diabetes 
TA B L E  1   Baseline characteristics of VKA users
 Starter Switcher P value
Total patients 1383 2786 NA
Age (years) 69.59	±	9.84 69.71	±	9.17 .69
Categorized by group   .12
Age	≥75 473 (34.20) 922 (33.11)  
Age	65‐74 497 (35.94) 1090 (39.14)  
Age	<65 413	(29.86) 773	(27.76)  
Gender female 592 (42.8) 938 (33.7) <.001
AF type   <.001
Paroxysmal AF 479 (35.0) 830 (29.8)  
Persistent AF 192 (14.0) 356	(12.8)  
Permanent AF 699	(51.0) 1598 (57.4)  
BMI (kg/m2) 28.95	±	5.61 29.55 ± 5.98 .002
Hypertension 1233 (89.2) 2295 (82.4) <.001
Prior TIA/Stroke/SE 386	(27.9) 740	(26.6) .36
Diabetes mellitus 335(24.2) 745	(26.7) .08
LV dysfunction 680	(49.2) 959 (34.4) <.001
Coronary artery disease 552 (42.2) 933 (34.1) <.001
Concomitant 
treatment
   
Aspirin 598 (43.2) 390 (14.0) <.001
Clopidogrel or 
Ticagrelor
45 (3.3) 30 (1.1) <.001
Other antiplatelet 10 (0.7) 10 (0.4) .17
TTR	(%) 51.86	±	22.49 60.08	±	21.46 <.001
Baseline creatinine 
clearance(ml/min)
87.78 ± 40.85 91.36	±	29.92 .001
Categorized by group    
<30 0 (0) 5 (0.18) <.001
30‐50 146	(10.66) 163	(5.90)  
50‐80 471 (34.40) 819	(29.66)  
≥80 752 (54.93) 1774	(64.25)  
CHA2DS2‐VASc score 4.07 ± 1.51 3.70 ± 1.52 <.001
0 0 (0) 0 (0) <.001
1 43 (3.1) 158 (5.7)  
2 167	(12.1) 476	(17.2)  
3 297	(21.6) 691	(24.9)  
4 358	(26.0) 660	(23.8)  
5 270	(19.6) 458	(16.5)  
≥6 240 (17.5) 331 (12.0)  
HAS‐BLED score 2.14 ± 1.04 1.75 ± 0.98 <.001
0 61	(4.4) 241 (8.7) <.001
1 311 (22.7) 922 (33.2)  
2 529 (38.5) 1029 (37.1)  
(Continues)
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mellitus, congestive heart failure and/or left ventricular impairment, 
previous stroke, hypertension, renal function (baseline creatinine 
clearance),	 suboptimal	 time	 in	 therapeutic	 range	 (TTR	 <	 60),	 and	
concomitant aspirin use, to account for the main parameters known 
to effect the efficacy and safety of oral anticoagulation. Model II 
was adjusted for the demographic parameters, which were signifi‐
cantly different between groups, sex, AF type, body mass index, 
hypertension, congestive heart failure and/or left ventricular im‐
pairment, symptomatic coronary artery disease, renal function 
(baseline creatinine clearance), TTR, concomitant aspirin use, and 
concomitant clopidogrel or ticagrelor use. Nelson‐Aalen estimates 
were used for the two groups comparisons and then Kaplan‐Meier 
curves were assessed using a Log‐rank test for the two‐group com‐
parison. A two‐tailed P value of <.05 was considered statistically 
significant. Analyses were performed using SPSS (version 23) and 
Stata (Version 13.0).
3  | RESULTS
After	merging	the	AMADEUS	and	BOREALIS	datasets,	4169	AF	pa‐
tients treated with VKA were available for analysis, including 1383 
“VKA	new	starters”	and	2786	“VKA	switchers”,	with	the	follow‐up	
of	365	±	187	days.	In	the	AMADEUS	dataset,	mean	follow‐up	was	
340	 ±	 165	 (median	 365[189‐460])	 days	 and	 396	 ±	 207	 (median	
399[211‐539])	days	in	BOREALIS	dataset.
In the “VKA new starters” group, there were significantly more 
females, and paroxysmal AF, prevalent hypertension, left ventric‐
ular dysfunction, coronary artery disease concomitant aspirin, 
clopidogrel, or ticagrelor use. “VKA new starters” had significantly 
lower body mass index, creatinine clearance, and TTR (Table 1). 
The characteristics of the patients by AMADEUS and BOREALIS 
datasets were not different to the pooled analysis (Table SI).
3.1 | Efficacy and safety outcomes
“VKA new starters” had higher crude rates of all‐cause mortality 
(P	 =	 .036)	 and	 cardiovascular	 death	 rates	 (P = .047) compared to 
“VKA switchers” (Table SII).
On multivariable Cox regression analysis, with “VKA switch‐
ers” used as reference, “VKA new starters” had nonsignificant 
risks of stroke/SE, major bleeding, and all‐cause death in Model 
I and Model II (Figure 1). Kaplan‐Meier survival curves did not 
show significant difference in stroke/SE (P = .09), major bleeding 
(P = .28), and all‐cause mortality (P	=	.06) between the two groups 
(Figure 2).
4  | DISCUSSION
In this ancillary analysis of the AMADEUS and BOREALIS trials, VKA 
“new starters” had a nonstatistically significant risk of stroke/SE and 
similar rates of major bleeding and all‐cause death compared with 
VKA “switchers”, after adjusting for associated comorbidities and 
risk factors. This is contrary to the perception that “new starters” 
and “switchers” were patients at higher risk of adverse outcomes. 
The strength of this analysis is the use of pooled individual patient 
data from two randomized, open‐label trials, with negligible sub‐
jective intention of switching between OACs and trial‐adjudicated 
outcomes.
With the development of NOACs and thus increased switch‐
ing from VKA to NOACs, benefits and risks among OAC switching 
F I G U R E  1   Forest plots for switchers and new starters 
comparison in the outcomes of stroke/SE, major bleeding, and 
all‐cause death. SE, systemic thromboembolism; VKA, vitamin K 
antagonists. See Statistics for covariates used in Model I and  
Model II
 Starter Switcher P value
3 337 (24.5) 474 (17.1)  
4 119 (8.7) 98 (3.5)  
≥5 16	(1.2) 9 (0.3)  
Note: Data were presented as mean ± SD or percentage of actual 
patients number.
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHA2DS2‐
VASc, congestive heart failure, 1 point; hypertension, 1 point; age 
≥75	years,	2	points;	diabetes	mellitus,	1	point;	stroke,	2	points;	vascular	
disease,	1	point;	age	from	65	to	74	years,	1	point;	and	female	sex,	1	
point;	HAS‐BLED,	uncontrolled	hypertension	(>160	mmHg	systolic),	1	
point; abnormal renal function, 1 point; or abnormal liver function, 1 
point; Prior history of stroke, 1 point; Prior major bleeding or predispo‐
sition to bleeding, 1 point; labile international normalised ratio, 1 point; 
age	>65	years,	1	point;	prior	alcohol	or	drug	usage	history	(≥8	drinks/
week), 1 point; medication usage predisposing to bleeding: (Antiplatelet 
agents, NSAIDs), 1 point; LV, left ventricle; SE, systemic thromboem‐
bolism; TIA, transient ischemic attack; TTR, time in therapeutic range; 
VKA, vitamin K antagonists.
TA B L E  1  (Continued)
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need to be carefully assessed.14 Relatively lower effectiveness and 
safety of “switchers” from VKA to NOACs compared to NOAC “new 
starters” have been reported, and have questioned whether the 
switching to NOACs is a marker of poor adherence and higher co‐
morbidity.8,10,15,16 As patients were randomly allocated to the study 
groups in the randomized trials, these concerns on adherence and 
comorbidities are reduced in the current analysis.
One previous study,16 mimicking a randomized study using a 
marginal structural model analysis, pointed out that no other bleed‐
ing risk except for gastrointestinal bleeding risk increased in patients 
who switched from VKA to dabigatran. The above results were 
broadly consistent with the large randomized trial with dabigatran, 
the Randomized Evaluation of Long‐Term Anticoagulant Therapy 
(RE‐LY) clinical trial.3 Subsequently, results of the RE‐LY trial were 
the basis of dabigatran approval by FDA.17
Previous “real‐world” studies suggested that the benefits ap‐
peared to be decreased in NOAC switchers, with the assumption 
of poor compliance or residual confounding from comorbidities 
among NOACs switchers.9,10 In the present ancillary pooled anal‐
ysis of AMADEUS and BOREALIS trials on a group of VKA‐treated 
patients only, those who were VKA starters had similar risks of 
stroke/SE, major bleeding, and all‐cause death compared with 
VKA switchers. The main difference of the present study com‐
pared with previous comparisons lies in the fact that there was 
no drug switching, but not whether they had prior VKA treatment 
history before their strict trial‐related follow‐up. This meant that 
F I G U R E  2   Nelson‐Aalen cumulative 
hazard ratios of stroke/SE, major bleeding, 
and all‐cause death. SE, systemic 
thromboembolism; VKA, vitamin K 
antagonists
     |  819BAI et Al.
benefits were not reduced and risks were not increased by prior 
VKA treatment history.
One point worth mentioning is that the higher risk of all‐cause 
mortality rates in “VKA new‐starters” was caused by higher burden 
of cardiovascular diseases. One possible reason could be that they 
were more likely to take antiplatelet agents (aspirin, clopidogrel) as 
their first antithrombotic choice, but not warfarin before random‐
ization. However, this significant difference disappeared after mul‐
tivariate adjustment.
4.1 | Switchers and starters from randomized trials
Studies are considered as having loss of precision if they only focus 
on new users in the evaluation of comparative effectiveness.18 In 
contrast, bias is increased by confounding in studies mainly focused 
on switchers. Randomized trials were composed of both starters 
and switchers in the two different trials at randomization, but this 
balance would be disrupted if comparisons were performed be‐
tween switchers and starters within drugs. Indeed, previous unad‐
justed meta‐analysis of VKA arms of randomized trials showed an 
increased risk of thromboembolism in VKA starters compared to 
VKA switchers.19 Two Cox regression models were therefore used 
to improve the accuracy of comparisons; subsequently, our analysis 
showed that switchers did not show any inferiority of effectiveness 
or safety in the two comparison settings (VKA switchers vs VKA 
new starters). Although new starters had an increased burden of car‐
diovascular diseases, leading to higher cardiovascular and all‐cause 
death rates, the safety and efficacy were not significantly different 
after multivariate adjustment.
4.2 | Limitations
There are several limitations for this study. First, this study lacked 
information of control quality of previous warfarin use and interna‐
tional normalised ratio (INR) values in bridging, 14 though labile INR 
was not the reason for the drug switching and switching between 
VKAs in both trials was without subjective intention. Also, we rec‐
ognize some differences in clinical characteristics between the two 
patient groups; nonetheless, these were adjusted in our Cox Model 
II. Second, information on anticoagulation bridging treatment (if any) 
was unavailable for both studies, which made us unable to provide 
information whether the current results were associated with over‐
lapped treatment or switching interval. Also, we did not have infor‐
mation on the OAC previously used in VKA switchers. Nevertheless, 
the negative results from the comparisons between VKA switchers 
and new starters help clarify their similar safety profile.
5  | CONCLUSIONS
In this post hoc analysis of clinical trial patients with AF, “new start‐
ers” and “switchers” for VKA initiation had nonstatistically signifi‐
cant rates of trial‐adjudicated outcomes of thromboembolism, major 
bleeding, and all‐cause mortality. This is contrary to the perception 
of healthcare professionals that “new starters” and “switchers” were 
patients at higher risk of adverse outcomes.
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